AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Uncover the best credit cards that offer fantastic rewards without an annual fee. Keep more money in your pocket while enjoying benefits.
28,035 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Wrtn is on track to exceed $100 million in annual recurring revenue this year, riding a loneliness-driven AI entertai...
As the market wrestles with SaaS cycles and AI disruption fears, monday.com stock has seen its share of monday blues....
Tesla posts stronger margins amid a delivery dip, while Rivian turns profitable on software and a hopeful R2 ramp. An...
As travel demand rebounds, investors want clarity on which cruise stock to buy in 2026. This guide contrasts Royal Ca...
Palantir Technologies is at a crossroads as AI-driven data analytics demand tightens. This long-range look maps 2026-...
A surprising shift in mega-cap leadership had investors buzzing: SpaceX briefly topped Amazon in market value. This p...
A new wave in AI infrastructure is building: the million-XPU data center. This article explains what it is, why it ma...
Palantir has moved from hero to a pullback phase. This guide breaks down what its valuation says about the future, wi...
AST SpaceMobile has captured attention with a surge tied to high-profile deals. This guide breaks down what the stock...
A breakthrough blood test that screens for 50+ cancers is edging toward real-world use. This article breaks down what...
Could one token rise to seven figures in the next decade? This article explores the idea, the logic behind it, and a ...